Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATA2271 |
Synonyms | |
Therapy Description |
ATA2271 (M28z1XXPD1DNR CAR T cells) consists of mesothelin-targeting chimeric antigen receptor (CAR) T cells with an ITAM motif-mutated CD3z signaling domain and a PD-1 dominant negative receptor (PD1DNR), which may enhance anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr LB-378). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATA2271 | M28z1XXPD1DNR CAR T cells | ATA2271 (M28z1XXPD1DNR CAR T cells) consists of mesothelin-targeting chimeric antigen receptor (CAR) T cells with an ITAM motif-mutated CD3z signaling domain and a PD-1 dominant negative receptor (PD1DNR), which may enhance anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr LB-378). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06623396 | Phase I | ATA2271 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | Recruiting | USA | 0 |
NCT04577326 | Phase I | ATA2271 Cyclophosphamide | Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma | Active, not recruiting | USA | 0 |